-

Viz.ai Wins 2023 Gold Edison Award™ for Innovation

Honored for excellence in innovation in AI Assisted Medicine

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced that it has been named a Gold Edison Award Winner in the 2023 Edison Awards. Viz Aneurysm, the company’s AI software solution designed to detect suspected cerebral aneurysms, was recognized in the AI Assisted Medicine category. The prestigious Edison Awards, named after the American inventor Thomas Alva Edison, honor excellence in new product and service development, marketing, design and innovation.

“We are incredibly honored to win our first Edison Award for innovation,” said Dr. Chris Mansi, CEO and co-founder of Viz.ai. “When we started Viz.ai, we had a vision that by leveraging artificial intelligence, we could help healthcare systems work smarter and faster, improving patient outcomes and ultimately saving lives. Every year in the United States, 30,000 patients suffer a ruptured aneurysm. This recognition of Viz Aneurysm, which has the potential to identify patients with aneurysms before they rupture, is a validation of our effort to make this vision a reality.”

Viz Aneurysm is the first intelligent care coordination software with an FDA-cleared, fully- automated, AI algorithm that detects suspected cerebral aneurysms which, if not actively monitored, are at risk for rupture. An estimated 6.7 million people in the United States have an unruptured brain aneurysm, or 1 in 50 people. Approximately 40% of people who have a brain aneurysm rupture will die, and 66% of the survivors will suffer permanent neurological deficits1. With mobile, HIPAA-compliant communication tools, Viz Aneurysm helps to ensure standardization of the aneurysm workflow across an entire health system, facilitating critical neurovascular treatment and follow-up care for at-risk patients.

All nominations are reviewed by the Edison Awards Steering Committee with the final ballot being determined by an independent judging panel. The panel is composed of more than 3,000 senior business executives and academics from the fields of product development, design, engineering, science, marketing and education, as well as past winners.

Winners were announced at the Edison Awards Gala on April 20, 2023 in Fort Myers, FL.

For more information on Viz Aneurysm, please visit https://www.viz.ai/aneurysm.

1 Brain aneurysm: What it is, causes, symptoms & treatment. Cleveland Clinic. (n.d.). Retrieved April 19, 2023, from https://my.clevelandclinic.org/health/diseases/16800-brain-aneurysm

About Viz.ai

Viz.ai is the pioneer in the use of AI algorithms and machine learning to increase the speed of diagnosis and care, covering more than 220 million lives across 1,300+ hospitals and health systems in the U.S. and Europe. The AI-powered Viz Platform is an intelligent care coordination solution that identifies more patients with a particular disease, informs critical decisions at the point of care, and optimizes care pathways and helps improve outcomes. Backed by real-world clinical evidence, the Viz Platform delivers significant value to patients, providers, and pharmaceutical and medical device companies. For more information visit viz.ai.

About The Edison Awards

Established in 1987, the Edison Awards is a program conducted by Edison Universe, a non-profit 501(c)(3) organization dedicated to fostering future innovators. The annual competition honors excellence in new product and service development, marketing, design and innovation. Past award recipients include Steve Jobs, Elon Musk, and leaders of global corporations such as Coca-Cola, Genentech, General Electric, General Motors, IBM and Campbell Soup Co. In 2022, the Edison Awards introduced the inaugural Lewis Latimer Fellowship program designed to celebrate, connect and bring together a community of innovative Black thought leaders. For more information, visit www.edisonawards.com.

Contacts

Viz.ai


Release Versions

Contacts

Social Media Profiles
More News From Viz.ai

A Decade of Increasing Access to Life Saving Treatments: Viz.ai Celebrates 10 Years, 2,000 Hospitals, and 230 Million Patients

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today celebrates its 10th anniversary, marking a decade of transforming how healthcare teams deliver care for patients. The company launched in 2016 to solve a key problem: variability in healthcare means that many patients fail to get guideline based care, even in life threatening diseases like stroke. Since achieving the first FDA clearance for an AI platform and increasing tr...

Viz.ai to Support the MINUTE Trial, a Landmark Multicenter Study Evaluating the SCUBA Technique for the Treatment of Intracerebral Hemorrhage

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced its support for the Minimally Invasive Neurosurgery Trial for Ultra-early Treatment (MINUTE) Trial, a prospective, multicenter, randomized study evaluating whether the SCUBA technique, an endoscopic, catheter-based approach for ultra-early evacuation of basal ganglia intracerebral hemorrhage (BGH), is a promising alternative to standard medical management to pote...

Viz.ai Expands into Neurodegenerative Disease with Cortechs.ai Collaboration

SAN FRANCISCO--(BUSINESS WIRE)--Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced a collaboration with Cortechs.ai, a global leader in neuroimaging and quantitative analysis solutions, to integrate Cortechs.ai's NeuroQuant and NeuroQuant MS suite into the Viz.ai platform, expanding access to quantitative neuroimaging for hospitals and health systems across the U.S. This partnership marks Viz.ai's expansion into neurodegenerative disease, growi...
Back to Newsroom